DLX-159

Last updated

DLX-159
Clinical data
Other namesDLX159
Routes of
administration
Oral [1] [2]
Drug class Psychoplastogen; Serotonin 5-HT2B receptor antagonist; Other undisclosed actions [2]

DLX-159 is a putatively non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and other psychiatric disorders. [1] [3] [2] It is taken by mouth. [1] [2]

The full mechanism of action of DLX-159 has yet to be disclosed. [1] [2] The drug shows psychoplastogenic effects in vitro and ex vivo . [2] These effects are blocked by the serotonin 5-HT2A receptor antagonst ketanserin as well as by the mTOR inhibitor rapamycin. [2] It also shows indications of psychoplastogenic effects in vivo in rodents. [2] In addition, similarly to ketamine, DLX-159 shows rapid antidepressant-like effects in the forced swim test (FST) in rodents that are present within 24 hours of a single dose and are sustained for at least 3 days. [2] DLX-159 also reversed the depression-like phenotype induced by chronic interferon alpha exposure in rodents. [2] DLX-159 does not produce the head-twitch response, and hence does not appear to have psychedelic effects. [2]

DLX-159 shows no signs of cardiotoxicity in preclinical studies. [2] It was assessed at the serotonin 5-HT2B receptor and was found to be an antagonist of this receptor. [2] It is said that further data on the pharmacological activity of DLX-159, including its activities at various receptors and enzymes, will be published in the future. [2] The drug is orally bioavailable and crosses the blood–brain barrier. [2]

DLX-159 is under development by Delix Therapeutics. [1] [3] [2] As of January 2025, it is in the preclinical research stage of development. [1] [3] The drug was first described in the scientific literature by December 2024. [2] Its chemical structure does not yet seem to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 7 "DLX 159". AdisInsight. 15 January 2025. Retrieved 31 January 2025.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Rasmussen K, Agrawal R, Felts A, Leach P, Gillie D, Mungenast A, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P252. DLX-159: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (207–207). doi: 10.1038/s41386-024-02011-0 . ISSN   0893-133X. PMC   11627186 . PMID   39643633 . Retrieved 31 January 2025.
  3. 1 2 3 "Delving into the Latest Updates on DLX-159 with Synapse". Synapse. 23 January 2025. Retrieved 31 January 2025.